Imunon, Inc. Increase (Decrease) in Accounts Payable and Accrued Liabilities
Imunon, Inc. (IMNN) reported Increase (Decrease) in Accounts Payable and Accrued Liabilities of -$1.53 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-11.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities · last filed 2026-08-11
- Imunon, Inc. increase (decrease) in accounts payable and accrued liabilities for the quarter ending 2026-06-30 was -$965.26K.
- Imunon, Inc. increase (decrease) in accounts payable and accrued liabilities for the quarter ending 2026-03-31 was -$567.16K, a 160.53% decline year-over-year.
- Imunon, Inc. increase (decrease) in accounts payable and accrued liabilities for the quarter ending 2025-12-31 was $320.23K.
- Imunon, Inc. increase (decrease) in accounts payable and accrued liabilities for the quarter ending 2025-09-30 was -$1.22M, a 590.54% decline year-over-year.
- Imunon, Inc. increase (decrease) in accounts payable and accrued liabilities for fiscal 2025 was -$521.12K.
- Imunon, Inc. increase (decrease) in accounts payable and accrued liabilities for fiscal 2024 was -$3.06M.
- Imunon, Inc. increase (decrease) in accounts payable and accrued liabilities for fiscal 2023 was -$1.99M.
| Period end | Increase (Decrease) in Accounts Payable and Accrued Liabilities 3 month | Increase (Decrease) in Accounts Payable and Accrued Liabilities 6 month | Increase (Decrease) in Accounts Payable and Accrued Liabilities 9 month | Increase (Decrease) in Accounts Payable and Accrued Liabilities 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$965.26K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-11 | -$1.53M 10-Q · filed 2026-08-11 | -$1.21M derived: sum of 3 quarters · filed 2026-08-11 | -$2.43M derived: sum of 4 quarters · filed 2026-08-11 |
| 2026-03-31 | -$567.16K 10-Q · filed 2026-05-12 | -$246.93K derived: sum of 2 quarters · filed 2026-05-12 | -$1.47M derived: sum of 3 quarters · filed 2026-05-12 | -$2.03M derived: sum of 4 quarters · filed 2026-08-11 |
| 2025-12-31 | $320.23K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-31 | -$902.24K derived: sum of 2 quarters · filed 2026-03-31 | -$1.46M derived: sum of 3 quarters · filed 2026-08-11 | -$521.12K 10-K · filed 2026-03-31 |
| 2025-09-30 | -$1.22M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-13 | -$1.78M derived: sum of 2 quarters · filed 2026-08-11 | -$841.35K 10-Q · filed 2025-11-13 | -$1.57M derived: sum of 4 quarters · filed 2026-08-11 |
| 2025-06-30 | -$555.88K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-11 | $381.12K 10-Q · filed 2026-08-11 | -$345.29K derived: sum of 3 quarters · filed 2026-08-11 | -$96.08K derived: sum of 4 quarters · filed 2026-08-11 |
| 2025-03-31 | $936.99K 10-Q · filed 2026-05-12 | $210.59K derived: sum of 2 quarters · filed 2026-05-12 | $459.80K derived: sum of 3 quarters · filed 2026-05-12 | $585.03K derived: sum of 4 quarters · filed 2026-05-12 |
| 2024-12-31 | -$726.40K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-31 | -$477.20K derived: sum of 2 quarters · filed 2026-03-31 | -$351.96K derived: sum of 3 quarters · filed 2026-03-31 | -$3.06M 10-K · filed 2026-03-31 |
| 2024-09-30 | $249.21K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-13 | $374.44K derived: sum of 2 quarters · filed 2025-11-13 | -$2.33M 10-Q · filed 2025-11-13 | -$383.22K derived: sum of 4 quarters · filed 2025-11-13 |
| 2024-06-30 | $125.24K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-05 | -$2.58M 10-Q · filed 2025-08-05 | -$632.42K derived: sum of 3 quarters · filed 2025-08-05 | -$1.76M derived: sum of 4 quarters · filed 2025-08-05 |
| 2024-03-31 | -$2.71M 10-Q · filed 2025-05-12 | -$757.66K derived: sum of 2 quarters · filed 2025-05-12 | -$1.89M derived: sum of 3 quarters · filed 2025-05-12 | -$4.06M derived: sum of 4 quarters · filed 2025-05-12 |
| 2023-12-31 | $1.95M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-27 | $818.13K derived: sum of 2 quarters · filed 2025-02-27 | -$1.35M derived: sum of 3 quarters · filed 2025-02-27 | -$1.99M 10-K · filed 2025-02-27 |
| 2023-09-30 | -$1.13M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-07 | -$3.30M derived: sum of 2 quarters · filed 2024-11-07 | -$3.94M 10-Q · filed 2024-11-07 | |
| 2023-06-30 | -$2.17M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-14 | -$2.81M 10-Q · filed 2024-08-14 | ||
| 2023-03-31 | -$638.79K 10-Q · filed 2024-05-13 | |||
| 2022-09-30 | $974.61K derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-14 | $1.26M derived: sum of 2 quarters · filed 2023-11-14 | $1.17M 10-Q · filed 2023-11-14 | |
| 2022-06-30 | $288.99K derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-10 | $193.98K 10-Q · filed 2023-08-10 | ||
| 2022-03-31 | -$95.01K 10-Q · filed 2023-05-11 | |||
| 2021-09-30 | $889.39K derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-14 | $1.30M derived: sum of 2 quarters · filed 2022-11-14 | $397.70K 10-Q · filed 2022-11-14 | |
| 2021-06-30 | $406.89K derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-15 | -$491.69K 10-Q · filed 2022-08-15 | ||
| 2021-03-31 | -$898.58K 10-Q · filed 2022-05-16 | |||
| 2020-09-30 | $79.52K derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-15 | -$361.80K derived: sum of 2 quarters · filed 2021-11-15 | -$866.75K 10-Q · filed 2021-11-15 | |
| 2020-06-30 | -$441.31K derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-12 | -$946.26K 10-Q · filed 2021-08-12 | ||
| 2020-03-31 | -$504.95K 10-Q · filed 2021-05-14 | |||
| 2019-09-30 | $462.40K derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-16 | $1.12M derived: sum of 2 quarters · filed 2020-11-16 | $486.86K 10-Q · filed 2020-11-16 | |
| 2019-06-30 | $659.65K derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-14 | $24.46K 10-Q · filed 2020-08-14 | ||
| 2019-03-31 | -$635.19K 10-Q · filed 2020-05-15 | |||
| 2018-09-30 | -$435.71K derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-14 | $166.01K derived: sum of 2 quarters · filed 2019-11-14 | -$399.94K 10-Q · filed 2019-11-14 | |
| 2018-06-30 | $601.72K derived: 10-Q 6 month − 10-Q 3 month · filed 2019-08-14 | $35.78K 10-Q · filed 2019-08-14 | ||
| 2018-03-31 | -$565.95K 10-Q · filed 2019-05-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| SOLIGENIX, INC. (SNGX) | United States | $0.008B | |
| EXICURE, INC. (XCUR) | United States | $0.008B | -1.54 |
| Traws Pharma, Inc. (TRAW) | United States | $0.009B | -0.58 |
| Alzamend Neuro, Inc. (ALZN) | United States | $0.009B | |
| Ensysce Biosciences, Inc. (ENSC) | United States | $0.008B | -0.37 |
| InMed Pharmaceuticals Inc. (INM) | $0.008B | -0.65 | |
| Apimeds Pharmaceuticals US, Inc. (APUS) | United States | $0.008B | |
| FibroBiologics, Inc. (FBLG) | United States | $0.009B | -0.27 |
| CNS Pharmaceuticals, Inc. (CNSP) | United States | $0.007B | |
| Acurx Pharmaceuticals, Inc. (ACXP) | United States | $0.007B | -0.97 |